Detalhe da pesquisa
1.
Consent document translation expense hinders inclusive clinical trial enrolment.
Nature
; 620(7975): 855-862, 2023 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-37532930
2.
Comprehensive tissue deconvolution of cell-free DNA by deep learning for disease diagnosis and monitoring.
Proc Natl Acad Sci U S A
; 120(28): e2305236120, 2023 07 11.
Artigo
Inglês
| MEDLINE | ID: mdl-37399400
3.
Sleep Disturbance as a Mediator of Lung Cancer Stigma on Psychological Distress and Physical Symptom Burden.
Psychosom Med
; 86(4): 334-341, 2024 May 01.
Artigo
Inglês
| MEDLINE | ID: mdl-38436657
4.
Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer.
N Engl J Med
; 383(10): 944-957, 2020 09 03.
Artigo
Inglês
| MEDLINE | ID: mdl-32877583
5.
Comparison of the tumor immune microenvironment and checkpoint blockade biomarkers between stage III and IV non-small cell lung cancer.
Cancer Immunol Immunother
; 72(2): 339-350, 2023 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-35881197
6.
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
N Engl J Med
; 378(22): 2078-2092, 2018 May 31.
Artigo
Inglês
| MEDLINE | ID: mdl-29658856
7.
Healthcare resource utilization in advanced non-small-cell lung cancer: post hoc analysis of the randomized phase 3 REVEL study.
Support Care Cancer
; 29(1): 117-125, 2021 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-32318871
8.
Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Lancet Oncol
; 21(3): 387-397, 2020 03.
Artigo
Inglês
| MEDLINE | ID: mdl-32035514
9.
Ramucirumab or placebo plus erlotinib in EGFR-mutated, metastatic non-small-cell lung cancer: East Asian subset of RELAY.
Cancer Sci
; 111(12): 4510-4525, 2020 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-32954593
10.
Knowledge Gaps and Research Priorities in Immune Checkpoint Inhibitor-related Pneumonitis. An Official American Thoracic Society Research Statement.
Am J Respir Crit Care Med
; 200(6): e31-e43, 2019 09 15.
Artigo
Inglês
| MEDLINE | ID: mdl-31518182
11.
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 20(12): 1655-1669, 2019 12.
Artigo
Inglês
| MEDLINE | ID: mdl-31591063
12.
Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial.
Lancet Oncol
; 20(11): 1544-1555, 2019 11.
Artigo
Inglês
| MEDLINE | ID: mdl-31563517
13.
Management of common adverse events related to first-line dacomitinib use in EGFR mutation-positive non-small-cell lung cancer: a pooled safety analysis.
Future Oncol
; 15(13): 1481-1491, 2019 May.
Artigo
Inglês
| MEDLINE | ID: mdl-30839234
14.
Rociletinib in EGFR-mutated non-small-cell lung cancer.
N Engl J Med
; 372(18): 1700-9, 2015 Apr 30.
Artigo
Inglês
| MEDLINE | ID: mdl-25923550
15.
Pembrolizumab for the treatment of non-small-cell lung cancer.
N Engl J Med
; 372(21): 2018-28, 2015 May 21.
Artigo
Inglês
| MEDLINE | ID: mdl-25891174
16.
Feasibility and Safety of Intrathoracic Biopsy and Repeat Biopsy for Evaluation of Programmed Cell Death Ligand-1 Expression for Immunotherapy in Non-Small Cell Lung Cancer.
Radiology
; 287(1): 326-332, 2018 04.
Artigo
Inglês
| MEDLINE | ID: mdl-29232184
17.
Highlights in non-small cell lung cancer from the IASLC 2023 World Conference on Lung Cancer: commentary.
Clin Adv Hematol Oncol
; 21 Suppl 5(10): 13-16, 2023 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-38307619
18.
Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.
Lancet Oncol
; 18(7): 895-903, 2017 07.
Artigo
Inglês
| MEDLINE | ID: mdl-28551359
19.
Non-small cell lung cancer clinical trials requiring biopsies with biomarker-specific results for enrollment provide unique challenges.
Cancer
; 123(24): 4800-4807, 2017 Dec 15.
Artigo
Inglês
| MEDLINE | ID: mdl-29125624
20.
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
Lancet
; 387(10027): 1540-1550, 2016 Apr 09.
Artigo
Inglês
| MEDLINE | ID: mdl-26712084